Clinical Trials Sponsored by Arlene Schmid

Total 446 results

Arlene Schmid

Withdrawn

Taking on Diabetes to Advance You (TODAY) (TODAY)

Type 2 Diabetes Mellitus

United States
Dr. Horst Schmidt Klinik GmbH

Recruiting

A Dual Tandem Study - SC vs. CAD-EYE vs. CAD-EYE With G-EYE

Adenoma | Colo-rectal Cancer

Germany
Dr. Horst Schmidt Klinik GmbH

Suspended

Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy

Patient Satisfaction | Intubating Conditions | Postoperative Myalgia

Germany
Dr. Horst Schmidt Klinik GmbH

Completed

Atrial Fibrillation and Neuropathic Pain After Thoracotomy and Continuous Application of Magnesium Sulphate.

Atrial Fibrillation | Neuropathic Pain

Germany
Dr. Horst Schmidt Klinik GmbH

Completed

Muscle Relaxation for Short Procedures

Patient Satisfaction | Sore Throat | Intubating Conditions | Postoperative Myalgia | Fasciculations

Germany
Dr. Horst Schmidt Klinik GmbH

Recruiting

Comparison of Colonoscopy Adenoma Detection Yield

Adenoma Colon

Germany
Dr. Horst Schmidt Klinik GmbH

Completed

Comparison of Adenoma Detection Rate With ENDOCUFF VISION® vs. G-EYE®

Colorectal Cancer | Adenoma

United States, Germany
Dr. Horst Schmidt Klinik GmbH

Completed

Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.

Chronic Pain | Acute Pain | Neuropathic Pain

Germany
Dr. Horst Schmidt Klinik GmbH

Completed

Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy

Intubating Conditions | Performance With Respiratory Exercise Device | Postoperative Myalgia

Germany
argenx

Not yet recruiting

A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

Myasthenia Gravis
argenx

Recruiting

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis (ADAPT SERON)

Generalized Myasthenia Gravis

United States
argenx

Recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy (ALKIVIA+)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

Korea, Republic of, United States, Bulgaria, Belgium, Denmark, Georgia, Greece, Lithuania, Argentina
argenx

Recruiting

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (VARVARA)

Delayed Graft Function

Australia, Spain, Belgium, Portugal, Canada
argenx

Recruiting

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD+)

Bullous Pemphigoid

Netherlands, Spain, Germany, United Kingdom, China, Italy, Hungary, United States, Croatia, Japan, Serbia, Bulgaria, Israel, Australia, Greece, Slovakia
argenx

Recruiting

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA+)

Multifocal Motor Neuropathy (MMN)

United Kingdom, Spain, United States, Italy, Netherlands, Germany, France, Belgium, Canada, Poland, Austria
argenx

Recruiting

Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis (ADAPT Jr +)

Generalized Myasthenia Gravis

United States, Netherlands, Belgium, Poland, United Kingdom
argenx

Active, not recruiting

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis (ADAPT NXT)

Generalized Myasthenia Gravis

Georgia, United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Poland, Spain
argenx

Active, not recruiting

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA)

Multifocal Motor Neuropathy

United States, France, Germany, Belgium, Italy, Netherlands, Canada, United Kingdom, Austria, Poland, Spain
argenx

Active, not recruiting

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid (BALLAD)

Bullous Pemphigoid

United States, Australia, Bulgaria, China, Croatia, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Serbia, Slovakia, Spain, United Kingdom
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
argenx

Completed

A Phase 1 Study to Compare the Safety and Effect of Efgartigimod as an Intravenous Infusion With the Effect of Efgartigimod as a Subcutaneous Injection in Healthy Volunteers

Healthy Volunteers

Netherlands
argenx

Completed

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Pemphigus Vulgaris | Pemphigus Foliaceus

Germany, Hungary, Israel, Italy, Ukraine
argenx

Withdrawn

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (ADVANCE2)

Primary Immune Thrombocytopenia (ITP)
argenx

Completed

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Healthy Volunteers

Netherlands
argenx

Completed

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Cancer

Belgium
argenx

Completed

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Cancer

Belgium
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease.

Thyroid Eye Disease

United States
argenx

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (empacific)

Myositis | Dermatomyositis
argenx

Recruiting

A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome

United States, Canada, France
argenx

Active, not recruiting

A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod

Renal Impairment

Germany
argenx

Active, not recruiting

Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis (ADAPTSC+)

Generalized Myasthenia Gravis

United States, Belgium, Czechia, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain
argenx

Completed

A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Australia, Bulgaria, China, France, Georgia, Germany, Greece, Hungary, India, Israel, Italy, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
argenx

Completed

Evaluating the Pharmacodynamic Noninferiority of Efgartigimod PH20 SC Administered Subcutaneously as Compared to Efgartigimod Administered Intravenously in Patients With Generalized Myasthenia Gravis (ADAPTsc)

Generalized Myasthenia Gravis

Spain, United States, Belgium, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation
argenx

Completed

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom
argenx

Completed

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Bioavailability Study

Netherlands
argenx

Recruiting

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Thyroid Eye Disease

United States
argenx

Not yet recruiting

A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.

Myasthenia Gravis
argenx

Recruiting

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Multifocal Motor Neuropathy

United States, Italy, Bulgaria, Latvia, Czechia, Poland, China, Serbia, Sweden
argenx

Recruiting

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Healthy Volunteers

Netherlands
argenx

Recruiting

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. (ALKIVIA)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Active Idiopathic Inflammatory Myopathy

United States, Germany, Spain, Korea, Republic of, Austria, Turkey, Lithuania, Australia, Thailand, Serbia, Poland, Italy, France, Netherlands, Argentina, United Kingdom, Georgia, Belgium, Bulgaria, Canada, Cyprus, Denmark, Greece, Hu... and more
argenx

Recruiting

Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United Kingdom, Spain, United States, Austria, Germany, Belgium, Italy, Netherlands, France, Georgia, Poland, Canada
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
argenx

Terminated

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus) (ADDRESS+)

Pemphigus Vulgaris | Pemphigus Foliaceus

United States, Germany, Italy, Australia, Bulgaria, China, France, Georgia, Greece, Hungary, India, Israel, Japan, Poland, Romania, Russian Federation, Serbia, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Phase 1 Bioequivalence Study of Efgartigimod PH20 SC Administered Via a Prefilled Syringe Versus a Vial+Syringe Presentation in Healthy Adults

Bioequivalence

United States
argenx

Completed

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Hungary, Israel, Italy, Japan, Latvia, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Taiwan, Turkey, Ukraine, United Kingdom
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
argenx

Completed

SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)

Healthy Volunteers

Netherlands

Clinical Trials Sponsored by Arlene Schmid

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations